On Friday, Del Frisco’s Restaurant Group Inc (NASDAQ:DFRG)’s shares inclined 1.77% to $19.02.
Del Frisco’s Restaurant Group, Inc. (DFRG) is happy to declare the appointment of Lane DeYoung as General Counsel. In the new position, Mr. DeYoung will be responsible for all internal and external legal matters that pertain to the Company and its restaurant brands, Del Frisco’s Double Eagle Steak House, Sullivan’s Steakhouse and Del Frisco’s Grille.
Mr. DeYoung most held the position of Associate General Counsel at Dave & Busters for the last eight years where he handled legal matters counting real estate leases, contracts, litigation, licensing and regulatory issues. Formerly, Mr. DeYoung served as Real Estate Counsel for FedEx Office and Print Services, Associate Regional Counsel for the Western Region at Trizec Properties, Associate Counsel at Stage Stores and Associate Attorney at The Law Offices of John E. Rapier, P.C. Mr. DeYoung holds a Doctorate of Jurisprudence from Texas Tech University School of Law and a Bachelor of Business Administration from Texas Tech University.
Del Frisco’s Restaurant Group, Inc. develops, owns, and operates restaurants in the United States. It owns and operates restaurants under the Del Frisco’s Double Eagle Steak House, Sullivan’s Steakhouse, and Del Frisco’s Grille brand names. The company offers steaks, in addition to other menu selections, such as chops and fresh seafood. As of June 1, 2015, it operated about 46 restaurants in 20 states and Washington, D.C. The company was founded in 1981 and is headquartered in Southlake, Texas.
MiMedx Group Inc (NASDAQ:MDXG)’s shares dropped -0.51% to $11.68.
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
S&P 500 constituent The Priceline Group Inc. (PCLN) will replace Baxter International Inc. (BAX) in the S&P 100, Baxalta Inc. (BXLT) will replace QEP Resources Inc. (QEP) in the S&P 500, QEP Resources will replace Itron Inc. (ITRI) in the S&P MidCap 400, and Itron will replace Arch Coal Inc. (ACI) in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. Baxter International is spinning off Baxalta in a transaction predictable to be accomplished on that date. Baxter International will remain in the S&P 500 following the distribution, but its post spin market capitalization will no longer make it appropriate for the S&P 100. QEP Resources, Itron and Arch Coal are all ranked near or at the bottom of their current indices.
Skechers USA Inc. (SKX) will replace Rock-Tenn Co. (RKT) in the S&P MidCap 400, and MiMedx Group Inc. (MDXG) will replace Skechers USA in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. S&P 500 constituent MeadWestvaco Corp. (MWV) is combining with Rock-Tenn in a transaction predictable to be accomplished on or about that date. The combined company will remain in the S&P 500 and will change its name to WestRock Co.
HealthEquity Inc. (HQY) will replace Zep Inc. (ZEP) in the S&P SmallCap 600 after the close of trading on Thursday, June 25. Private equity firm New Mountain Capital is acquiring Zep in a transaction predictable to be accomplished on or about that date pending final approvals.
The Priceline Group provides online travel and travel related reservation and search services.
Baxalta develops and markets innovative biopharmaceuticals. Headquartered in Deerfield, IL, the company will be added to the S&P 500 GICS (Global Industry Classification Standard) Biopharmaceuticals Sub-Industry index.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
At the end of Friday’s trade, Abengoa Yield PLC (NASDAQ:ABY)‘s shares dipped -3.37% to $33.86.
Abengoa Yield (ABY), the sustainable total return company that owns a diversified portfolio of contracted assets in the energy and environment sectors, declared recently that it has been assigned a corporate credit rating of BB+ with a stable outlook by Standard & Poor’s Rating Services. Additionally, Abengoa Yield senior unsecured notes due in 2019 were also assigned the same BB+ credit rating and the senior secured credit facility due in 2018 was assigned a BBB rating.
Standard & Poor’s highlighted in its press release the credit strength of a portfolio of renewable and conventional generation and electric transmission assets that generate stable cash flow from long-term revenue contracted assets with highly rated counterparties.
Abengoa Yield plc owns a portfolio of renewable energy, conventional power, and electric transmission line contracted assets in North America, South America, and Europe. The company’s renewable energy assets comprise 2 solar power plants each with a gross capacity of 280 megawatts (MW) in the United States; 1 on-shore wind farm with a gross capacity of 50 MW in Uruguay; and 2 solar power plants each with a gross capacity of 50 MW in Spain. Its conventional power asset comprises a 300 MW cogeneration plant in Mexico.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), ended its Friday’s trading session with -1.59% loss, and closed at $17.90.
Amphastar Pharmaceuticals, Inc. (AMPH) declared that the U.S. Food and Drug Administration (“FDA”) granted approval of the Company’s New Drug Application (“NDA”) supplement for Amphadase(R) (hyaluronidase injection). This marks the first FDA approved starting material from the Company’s partner, ANP, located in Nanjing, China, and signifies that this facility has been qualified by the FDA.
Amphadase(R) will compete in the hyaluronidase market, which had sales of $23 million for the 12 months ended March 31, 2015, according to IMS Health sales data. The product is used to improve the resorption of radiopaque agents. Amphastar plans to re-launch Amphadase(R) in the fourth quarter of 2015.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
